---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-035189"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2026-09-01T13:00:28+00:00"
generated_at: "2026-09-01T13:02:04.339649+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.05
calibrated_materiality_score: 0.05
confidence: "low"
source: SEC EDGAR
---

# Gyre Therapeutics posts updated corporate presentation; no new material facts disclosed

## Summary
- Company posted updated corporate presentation dated September 2026 on its website on September 1, 2026.
- Presentation furnished as Exhibit 99.1; exhibit body text appears truncated in filing, so no specific figures available.
- No financial results, guidance, or business developments are disclosed in the furnished exhibit text.
- Filing signed by CFO Thomas Eastling.

## SEC filing metadata
- accession: 0001140361-26-035189
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2026-09-01T13:00:28+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.05
- calibrated_materiality_score: 0.05
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000114036126035189/0001140361-26-035189-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000114036126035189/ef20081441_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-035189
- JSON: https://secwatch.observer/filing/0001140361-26-035189.json
- Plain text: https://secwatch.observer/filing/0001140361-26-035189.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.